Tanvex BioPharma Inc (6541) - Total Liabilities

Latest as of March 2026: NT$2.27 Billion TWD ≈ $71.64 Million USD

Based on the latest financial reports, Tanvex BioPharma Inc (6541) has total liabilities worth NT$2.27 Billion TWD (≈ $71.64 Million USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.

Tanvex BioPharma Inc - Total Liabilities Trend (2013–2025)

This chart illustrates how Tanvex BioPharma Inc's total liabilities have evolved over time, based on quarterly financial data. See working capital position of Tanvex BioPharma Inc to evaluate short-term liquidity relative to the company's equity base.

Tanvex BioPharma Inc Competitors by Total Liabilities

The table below lists competitors of Tanvex BioPharma Inc ranked by their total liabilities.

Company	Country	Total Liabilities
Balmer Lawrie & Company Limited NSE:BALMLAWRIE	India	Rs12.69 Billion
Prince Pipes And Fittings Limited NSE:PRINCEPIPE	India	Rs7.79 Billion
Borussia Dortmund GmbH & Co KGaA XETRA:BVB	Germany	€289.44 Million
Chengdu Huasun Group Inc Ltd SHE:000790	China	CN¥911.88 Million
A-LIVING SM.CI.SV. H YC 1 F:1V0	Germany	€9.07 Billion
Telos Corp NASDAQ:TLS	USA	$43.91 Million
Yuen Foong Yu Consumer Prod TW:6790	Taiwan	NT$4.66 Billion
Zhejiang Busen Garments Co Ltd SHE:002569	China	CN¥179.11 Million

Liability Composition Analysis (2013–2025)

This chart breaks down Tanvex BioPharma Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see Tanvex BioPharma Inc market capitalisation.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	1.33	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.42	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.30	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Tanvex BioPharma Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Tanvex BioPharma Inc (2013–2025)

The table below shows the annual total liabilities of Tanvex BioPharma Inc from 2013 to 2025.

Year	Total Liabilities	Change
2025-12-31	NT$2.27 Billion ≈ $71.43 Million	+23.09%
2024-12-31	NT$1.84 Billion ≈ $58.03 Million	-5.17%
2023-12-31	NT$1.94 Billion ≈ $61.19 Million	-4.24%
2022-12-31	NT$2.03 Billion ≈ $63.90 Million	+5.71%
2021-12-31	NT$1.92 Billion ≈ $60.45 Million	+9.52%
2020-12-31	NT$1.75 Billion ≈ $55.20 Million	+223.18%
2019-12-31	NT$542.12 Million ≈ $17.08 Million	+105.41%
2018-12-31	NT$263.92 Million ≈ $8.31 Million	+17.93%
2017-12-31	NT$223.78 Million ≈ $7.05 Million	-25.22%
2016-12-31	NT$299.25 Million ≈ $9.43 Million	+146.47%
2015-12-31	NT$121.41 Million ≈ $3.83 Million	+86.52%
2014-12-31	NT$65.09 Million ≈ $2.05 Million	-22.16%
2013-12-31	NT$83.63 Million ≈ $2.63 Million	--

About Tanvex BioPharma Inc

TW:6541 Taiwan Biotechnology

Market Cap

$337.70 Million

NT$10.72 Billion TWD

Market Cap Rank

#14365 Global

#614 in Taiwan

Share Price

NT$40.45

Change (1 day)

-0.12%

52-Week Range

NT$37.40 - NT$65.30

All Time High

NT$287.73